Cyclophosphamide
CNS Disease
Reva BashoSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the CNS Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sagopilone Nancy Lin, MD | Phase 2 | CCC |
Capecitabine National University Hospital, Singapore | Phase 1/2 | CCC |
TRASTUZUMAB Reva Basho | Phase 1/2 | CCC |
Tucatinib Reva Basho | Phase 1/2 | CCC |
Pembrolizumab Reva Basho | Phase 1/2 | CCC |
Tislelizumab National University Hospital, Singapore | Phase 1/2 | CCC |
Epirubicin Reva Basho | Phase 1/2 | CCC |
Dasatinib M.D. Anderson Cancer Center | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →